Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
First-in-Class B-Cell Depleting Agent Promising for MG
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized myasthenia gravis (gMG), new phase 3 data showed. “Based on these results, we have demonstrated that…
English